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Abstract
Background: Numerous studies have attempted to relate genetic polymorphisms within the N-
acetyltransferase 2 gene (NAT2) to interindividual differences in response to drugs or in disease
susceptibility. However, genotyping of individuals single-nucleotide polymorphisms (SNPs) alone
may not always provide enough information to reach these goals. It is important to link SNPs in
terms of haplotypes which carry more information about the genotype-phenotype relationship.
Special analytical techniques have been designed to unequivocally determine the allocation of
mutations to either DNA strand. However, molecular haplotyping methods are labour-intensive
and expensive and do not appear to be good candidates for routine clinical applications. A cheap
and relatively straightforward alternative is the use of computational algorithms. The objective of
this study was to assess the performance of the computational approach in NAT2  haplotype
reconstruction from phase-unknown genotype data, for population samples of various ethnic
origin.
Results: We empirically evaluated the effectiveness of four haplotyping algorithms in predicting
haplotype phases at NAT2, by comparing the results with those directly obtained through molecular
haplotyping. All computational methods provided remarkably accurate and reliable estimates for
NAT2 haplotype frequencies and individual haplotype phases. The Bayesian algorithm implemented
in the PHASE program performed the best.
Conclusion:  This investigation provides a solid basis for the confident and rational use of
computational methods which appear to be a good alternative to infer haplotype phases in the
particular case of the NAT2 gene, where there is near complete linkage disequilibrium between
polymorphic markers.
Background
N-acetylation polymorphism is one of the earliest discov-
ered and most intensively studied pharmacogenetic traits
that underlie interindividual and interethnic differences
in response to xenobiotics. In humans, acetylation is a
major route of biotransformation for many arylamine and
hydrazine drugs, as well as for a number of toxins and
known carcinogens present in the diet, cigarette smoke
and the environment [1-3]. Genetically determined differ-
ences in N-acetylation capacity have been proved to be
important determinants of both the effectiveness of ther-
apeutic response and the development of adverse drug
reactions and toxicity during drug treatment [4]. In the
last decades, numerous investigations have been made to
elucidate the genetic basis of N-acetylation polymor-
phism in various ethnic groups in order to develop
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efficient genotyping tests and to adapt therapies to specific
patients and populations in accordance with their genetic
makeup. Some of the drugs excreted by acetylation are
indeed crucial in the treatment of diseases representing a
worldwide concern, such as tuberculosis and AIDS-related
complex diseases [5,6]. Moreover, a number of epidemio-
logical studies have suggested possible associations
between the N-acetylator phenotype and a variety of com-
plex human diseases, the most consistent findings being
those regarding urinary bladder cancer and familial Par-
kinson's disease [7-10].
The gene coding for the arylamine N-acetyltransferase 2
(NAT2) enzyme has been established as the site of the
classic human acetylation polymorphism [11-13] and the
molecular basis of individual and interethnic variation in
acetylation capacity is now well documented [14,15]. All
mutations reported to date are found within the 870-bp
coding region of the NAT2 gene. Among the seven single
nucleotide polymorphisms (SNPs) that are commonly
found in human populations, four result in an amino acid
substitution that leads to a significant decrease in acetyla-
tion capacity (single base-pair substitutions at positions
191, 341, 590, 857). The other three are either silent
mutations (C282T, C481T) or a non-synonymous substi-
tution that does not alter phenotype (A803G).
In the consensus gene nomenclature of human NAT2 that
encompasses all currently recognized alleles [16,17], sets
of SNPs located throughout the coding region are linked
in terms of haplotypes, that is they are organized as they
segregate together on one individual's chromosome at the
NAT2 locus. Each combination of SNPs identified so far
constitutes a distinct haplotype that is treated as an allele
of the haplotype system. The consideration of multilocus
haplotypes seems more desirable since there is growing
evidence that for genes containing multiple SNPs in high
linkage disequilibrium (LD) such as NAT2 [18], haplo-
type structure rather than individual SNPs can be the prin-
cipal determinant of phenotypic consequences [19-21]. A
functional polypeptide is indeed the product of a haplo-
type, covering the entire coding region and coded by a sin-
gle chromosome.
The NAT2 alleles described so far contain up to four of the
acknowledged mutations in various combinations. Each
allele is associated with an acetylator phenotype depend-
ing on which mutations they contain: for instance, substi-
tutions at positions 191, 341, 590, and 857 are diagnostic
for defective NAT2  function and hence for the slow
acetylator phenotype (Table 1). Three NAT2 phenotypes
have been described: subjects with two low activity alleles
are classified as slow acetylators, while those with two
functional alleles are considered rapid acetylators. If only
one allele is of the slow type, an intermediate phenotype
is observed. Many early studies did not distinguish
between fast and intermediate acetylators, categorizing
both types of subjects as fast acetylators.
Table 1: The major human NAT2 alleles and their associated phenotypea.
Allele Nucleotide change b Phenotype
G191A C282T T341C C481T G590A A803G G857A
NAT2*4 rapid
NAT2*5A x x slow
NAT2*5B x xx s l o w
NAT2*5C x x slow
NAT2*6A x x slow
NAT2*6B x slow
NAT2*7A x slow
NAT2*7B x x slow
NAT2*12A x rapid
NAT2*12B x x rapid
NAT2*13 x rapid
NAT2*14A x slow
NAT2*14B x x slow
Nucleotide substitutions shown in bold have a functional consequence on enzyme activity. Bold-faced alleles contain functional polymorphisms and 
are hence associated with the slow acetylator phenotype. Classification of NAT2 alleles into different clusters is based on the most functionally 
significant nucleotide substitution present: the NAT2*5, NAT2*6, NAT2*7 and NAT2*14 clusters possess signature nucleotide substitutions at 
positions 341, 590, 857 and 191, respectively and are hence all decreased function alleles ('slow alleles'). The others display enzymatic activity 
comparable to the rapid acetylator allele NAT2*4. There are significant interethnic differences in NAT2 allele distribution and frequency [14, 15].
a Adapted from Hein et al. [3]. NAT2 nomenclature is accessible on the internet at website http://www.louisville.edu/medschool/pharmacology/
NAT.html
b Only changes from the reference sequence (NAT2*4) are indicated.BMC Genetics 2005, 6:30 http://www.biomedcentral.com/1471-2156/6/30
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Problems may occur when individual multi-site NAT2
genotypes have to be assigned correctly to a particular
combination of two multilocus haplotypes. Indeed, cur-
rent routine genotyping and sequencing methods typi-
cally do not provide haplotype information in diploid
organisms such as humans, and the gametic phase of hap-
lotypes is inherently ambiguous when individuals are het-
erozygous at more than one locus. As illustrated in Figure
1, a subject carrying two inactivating mutations can be
either rapid or slow acetylator depending on whether
these mutations are located in the same or different chro-
mosome, respectively. It is thus crucial to unequivocally
assess mutation linkage patterns, this step being a prereq-
uisite to obtain accurate haplotype frequency estimates in
populations and reliable genotype-phenotype
predictions.
However, in spite of its high relevance, this issue has not
been handled properly by most past studies investigating
NAT2  polymorphisms. Early genotyping studies only
screened for the presence of three polymorphisms
(C481T, G590A, G857A), and a subject was defined as a
slow acetylator if he was homozygous for one, or hetero-
zygous for two (each located on one DNA strand), of this
three nucleotide changes. Such a definition assumed that
there could be no single allele with two or more of the
tested mutations. In other studies that screened a larger
number of SNPs within NAT2, patterns of LD between
point mutations were often assumed, in reference to the
haplotypes previously described and which are com-
monly found in populations of European origin. For
instance, the designation of NAT2 alleles is usually based
on the assumption that 481T and 803G are strongly
linked to 341T, and 590A and 857A are linked to 282T
[22]. However, in rare cases the typical allelic linkage pat-
tern of mutations may be disrupted because of genetic
recombination and this may result in misclassification of
alleles. Indeed, although such assumed linkage patterns
are very strong, other allelic variants carrying either unu-
sual combinations of mutations or mutations in isolation
have been described in a few cases [23]. Furthermore, the
designation of NAT2 alleles in such a way that it necessar-
ily conforms to the existing consensus nomenclature of
acknowledged haplotypes precludes the disclosure of
unexpected combinations of mutations, different from
the established allelic variants, and hence, the discovery of
new alleles. Such a manner of inferring haplotypes from
unphased multilocus genotypes may introduce biases in
NAT2 allele designation and individual phenotype pre-
diction, and these potential biases are of higher magni-
tude when non-European populations are concerned.
Most studies assumed particular patterns of linkage previ-
ously described in populations of European origin, but
which may not hold in other ethnic groups. Indeed, recent
works have shown that patterns of LD can differ markedly
among populations with different ethnic and demo-
graphic backgrounds. As an example, Loktionov and col-
leagues [24] pointed out the high occurence of isolated
mutations 803G and 282T (defining alleles NAT2*12A
and NAT2*13, respectively) in Black South Africans, while
these nucleotide changes are almost always tightly linked
to other mutations in European populations [25]. Like-
wise, Dandara et al. [26] recently identified a novel muta-
tion linkage pattern (NAT2*6E) that appeared to be
common in three African populations and that had not
yet been reported in Europeans. As well, Anitha et al. [27]
revealed a new combination of acknowledged mutations
(NAT2*5G) in the Malapandaram tribe of South India
that has not been described so far in any other world pop-
ulation. The genotype-phenotype discordance observed in
many ethnic groups where mutation linkages have not
been extensively proven experimentally might result from
such unexpected compound alleles. It is thus necessary to
systematically verify the postulated allelic combinations.
The ambiguous gametic phase of haplotypes for a given multi- locus genotype Figure 1
The ambiguous gametic phase of haplotypes for a given multi-
locus genotype. To illustrate the relevance of linkage phase 
ascertainment, let us consider the following case of a four-
site heterozygous individual at positions 191, 341, 481 and 
803 within the NAT2 coding sequence. Eight possible combi-
nations of haplotypes can be inferred from this multilocus 
genotype, two of whom are shown here. Depending on the 
location of mutations to either DNA strand, the individual's 
NAT2 genotype composed of two multilocus haplotypes will 
not be the same. Moreover, an incorrect resolution of muta-
tion linkage patterns may entail an error in individual pheno-
type prediction: the subject will be classified either as a slow 
or as a rapid acetylator depending on the haplotypic combi-
nation chosen. Symbol (*) points at mutations leading to a 
decrease in NAT2 enzyme activity, while symbol (×) indicates 
those with no impact on the acetylator phenotype.
*5B *14A *14C *4



 191 191 or
341 341
481 481
803 803
Individual with a rapid 
acetylator genotype 
NAT2*4 / NAT2*14C
(one ‘rapid’ allele)
Individual with a slow 
acetylator genotype 
NAT2*14A / NAT2*5B
(two ‘slow’ alleles)BMC Genetics 2005, 6:30 http://www.biomedcentral.com/1471-2156/6/30
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To avoid such potential problems, many authors designed
special analytical techniques to unequivocally determine
the allocation of mutations to either DNA strand. Molec-
ular methods using combinations of mutation-specific
polymerase chain reaction (PCR) reamplification coupled
to restriction mapping of the PCR products have been
developed; these allow the separate analysis of each allele
in order to obtain a complete map of both genes in every
individual. Some studies applied these procedures to all
multiply heterozygous subjects [24,28-31], while others
limited their application to particular cases as those where
an alternative linkage pattern of mutations would lead to
a change in phenotype [5,27,32-36]. However, these
experimental methods of molecular haplotyping are not
entirely satisfying because they entail an additional cost
and are currently labour-intensive, time-consuming,
prone to experimental errors and difficult to automate.
Therefore, they do not appear to be good candidates for
routine clinical applications and for a generalization at a
large scale.
A cheap and relatively straightforward alternative for hap-
lotype reconstruction based on genotype data from unre-
lated individuals is the use of computational algorithms.
The most widely used algorithms developed so far are
based either on a parsimony, a maximum-likelihood, or a
Bayesian approach (see [37] for a review). In the last dec-
ade, numerous investigations based on empirical data and
extensive simulation studies have demonstrated that such
in silico haplotype-inference methods could give effective
and accurate prediction of haplotype phases, especially in
regions with high LD values between polymorphic sites
and small probabilities of recombination events
[18,38,39]. Therefore, they could be fairly efficient alter-
natives to molecular-haplotyping methods when applied
to NAT2 gene data. Surprisingly, to our knowledge, only
three studies have used computational methods to recon-
struct NAT2 haplotypes and estimate allele frequencies in
population samples [40-42]. One explanation for such
limited use may be the lack of evidence documenting the
performance of in silico approaches when applied to
actual NAT2 data. Indeed, the accuracy of these strategies,
compared with molecular methods, needs to be assessed
before their applications can be advocated at a large scale.
A recent study provided preliminary results on this issue:
Xu and colleagues [18] empirically evaluated and com-
pared the accuracy of the Clark's algorithm [43], the
expectation-maximisation (EM) algorithm and a Bayesian
method implemented in the PHASE program [44] in
phase inference at NAT2, taken as an example of a locus
with pronounced LD over a 850-bp region. In this study,
NAT2 haplotypes (consisting of five genotyping SNPs at
position 282, 341, 481, 590, and 803 nt) were experimen-
tally determined through cloning and sequencing in 81
individuals of European ancestry. They found that all
three computational methods provided remarkably accu-
rate and reliable estimates for NAT2 haplotype frequen-
cies and individual haplotype phases.
The objective of the present study was to extend this inves-
tigation to more precisely assess the performance of the
computational approach. We conducted an extensive
study based on experimental data from a larger number of
samples, issued from populations of various ethnic origin,
and tested for haplotypes involving the seven major poly-
morphic loci of NAT2. Furthermore, the larger population
samples investigated are of greater significance: as the
sample size grows, there is more opportunity to observe
rare haplotypes that are the most difficult to infer statisti-
cally. This comparative study is designed to evaluate the
performance of different haplotyping algorithms and to
assess the consistency of their estimates. In addition, it
provides information on the impact of various data-set
characteristics (sample size, haplotype frequency distribu-
tion, haplotype frequencies, deviation from Hardy-Wein-
berg (HW) equilibrium, ...) on estimation accuracy; we
then explore the utility of data-based diagnostics for
assessing probable accuracy.
Results
Molecular haplotyping of the NAT2  locus revealed
between eight and twelve distinct haplotypes in each of
the five population samples investigated. The theoretical
maximum number of haplotypes for a set of seven bial-
lelic variable sites is 128 (27) if there is random associa-
tion between polymorphic sites, whereas it is only 8 in the
absence of recombination, recurrent and back mutation.
Hence, the small number of haplotypes observed at NAT2
suggests strong LD over the short physical distance span-
ning this gene. Indeed, we observed complete or near
complete LD for all pairs of SNPs with sufficiently high
frequencies (only alleles with frequencies in the range
0.05–0.95 were included in the analysis because estimates
of LD for low-frequency alleles in small samples are not
informative): 85% of all pairwise r2 values were highly sig-
nificant (Exact p-value <0.0001). Although LD patterns
were rather similar among the different population sam-
ples, substantial differences in LD levels were observed
(Figure 2): the Korean sample, and especially the South
African sample, displayed much smaller values of average
pairwise r2 (0.27 and 0.20, respectively) than the two
European and the Nicaraguan samples (values between
0.39 and 0.57), for which a strong haplotypic structure
was observed.
Among the 1608 individuals investigated over the five
data sets, 45.5% (732/1608) were either homozygous for
all SNP sites or heterozygous at only one SNP site; thus,
their haplotype pairs could be assigned directly. Besides,
35.7% (574), 10.0% (160), 0.9% (15), and 7.9% (127)BMC Genetics 2005, 6:30 http://www.biomedcentral.com/1471-2156/6/30
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individuals were heterozygous at two, three, four and five
SNP sites, respectively. We inferred their haplotype phases
with four computational haplotyping methods, and
compared the results with those obtained through molec-
ular haplotyping.
Since the Hapar program often provided several equally
parsimonious solutions for a given multilocus genotype,
it could not resolve a relatively large fraction of hetero-
zygous individuals in each sample and hence, we could
not deduce frequency estimates for the haplotypes
Linkage disequilibrium (r2 value) between SNP markers in the NAT2 locus Figure 2
Linkage disequilibrium (r2 value) between SNP markers in the NAT2 locus. Graphical representation of the disequilibrium 
matrices obtained through computation of the r2 coefficient between each pair of markers, for the Spanish, Korean and Black 
South African samples. The British and Nicaraguan samples provided patterns and levels of LD comparable to those of the 
Spanish data. For each marker pair, GOLD [60] plotted the color-coded pairwise r2 statistics at the Cartesian coordinates cor-
responding to marker location, and the plots were completed by interpolation. These graphs point out the strong level of LD 
between markers at positions 341, 481, and 803, as well as between SNPs located at 282 and 590: these markers are thus 
strongly predictive of one another. In Black South Africans, LD patterns are less pronounced and more diffuse across marker 
pairs.
Table 2: The five phase-resolved NAT2 molecular data sets investigated.
Population sample Proportion of phase-unknown 
multiple heterozygotesa
NAT2 gene diversityb Deviation from the Hardy-
Weinberg equilibrium (exact 
p-value)c
258 Spanish [45] 66.7% 0.65 0.012
137 Nicaraguans [30] 59.1% 0.70 0.072
112 UK Caucasians [24] 52.7% 0.69 0.222
101 Black South Africans [24] 63.4% 0.86 0.122
1000 Koreans [31] 50.0% 0.52 0.016
All population samples were genotyped for the same seven nucleotide changes (G191A, C282T, T341C, C481T, G590A, A803G, G857A), except 
Koreans where the C190T mutation was investigated instead of G191A.
aProportion of multiply heterozygous individuals with ambiguous genotype whose phase has been resolved molecularly.
bExpected heterozygosities for the NAT2 haplotyped system were estimated as   where n is the number of gene copies in the 
sample, and pi is the sample frequency of the i-th haplotype.
cThe significance of deviations from Hardy-Weinberg equilibrium was tested for genotypic data with known gametic phase using the random-
permutation procedure implemented in the Arlequin package [51]: a Fisher's exact test using a Markov chain random walk algorithm was performed 
for each data set. The resulting p-values were considered significant if inferior to 0.05 (significant p-values are shown in bold).
101 Black South Africans 1000 Koreans 258 Spanish
n
n-1
pi
2 1− () ∑BMC Genetics 2005, 6:30 http://www.biomedcentral.com/1471-2156/6/30
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observed. Therefore, we evaluated Hapar only on its abil-
ity to identify the set of haplotypes present in a sample.
Haplotype identification
Hapar found for each sample the smallest set of haplo-
types that could explain the genotype data, and PL-EM,
Haplotyper and PHASE provided the list of all the haplo-
types selected to appear in at least one of the subjects in
the "best" reconstruction, that is when the most likely pair
of haplotypes is selected for each individual. The IH indi-
ces of the four programs are displayed for each population
sample in Table 3. For the British and Korean samples, all
computational methods identified exactly the same hap-
lotypes as those determined experimentally. In contrast,
in the other three samples, the algorithms sometimes
inferred one additional haplotype, that was not actually
present, and/or missed one haplotype that was shown to
be present by means of molecular haplotyping. Neverthe-
less, these prediction errors always concerned rare haplo-
types of frequency <0.75% (singletons in most cases). The
PHASE algorithm performed the best.
Prediction of individual haplotype phases
We also evaluated and compared the effectiveness of the
computational methods in reconstructing haplotype pairs
for individuals. Table 4 gives, for each data set and for
each algorithm, the individual error rate. Whatever the
method, the number of incorrectly reconstructed individ-
uals was remarkably low, with error rates always under
4%. The largest number of mistakes were observed for the
African sample and, among the three algorithms tested,
PHASE yielded the lowest error rates. Furthermore, it is
interesting to note that, in all cases of incorrectly predicted
phases, there was no impact on phenotype prediction.
Thus, despite these errors, the proportions of slow, inter-
mediate and rapid acetylators in each population sample
Table 3: Performance of the four computational methods in haplotype identification, as measured by the IH index.
Hapar PL-EM Haplotyper PHASE
258 Spanish [45] 0.933 (1) 0.933 (1) 0.933 (1) 0.933 (1)
137 Nicaraguans [30] 0.952 (1) 0.952 (1) 0.909 (2) 0.952 (1)
112 UK Caucasians [24] 1 1 1 1
101 Black South Africans [24] 0.917 (2) 0.917 (2) 0.917 (2) 1
1000 Koreans [31] - * 1 1 1
Numbers in brackets indicate the number of haplotypes for which an error of prediction was made. * The size of the Korean sample was too large 
to be correctly handled by the Hapar program.
Table 4: Individual error rate in haplotype reconstruction
PL-EM Haplotyper PHASE
258 Spanish [45] 0.39% 0.39% 0.39%
137 Nicaraguans [30] 2.19% 3.65% 2.19%
112 UK Caucasians [24] 0.89% 0% 0%
101 Black South Africans [24] 3.96% 3.96% 2.97%
1000 Koreans [31] 0.30% 0.30% 0.30%
The individual error rate is defined as the ratio of erroneous phase calls to the total number of phase calls (see text).
Table 5: Index of similarity (IF) between haplotype frequencies 
estimated with and without molecular haplotyping information.
PL-EM PHASE
258 Spanish [45] 0.996 0.996
137 Nicaraguans [30] 0.986 0.986
112 UK Caucasians [24] 0.994 0.998
101 Black South Africans [24] 0.981 0.988
1000 Koreans [31] 0.997 0.998
Computations of IF indices were based on the haplotype frequency 
estimates obtained by considering all possible haplotype 
configurations (with a nonzero probability) inferred for each subject, 
weighted by their estimated probability. Note that such estimates can 
be rather different from those obtained by gene counting on the basis 
of the "best" reconstruction (that is, when only the most probable 
pair of haplotype is selected for each sampled individual). Since 
Haplotyper only provides a summary of the frequency with which 
each haplotype occurred in the "best" reconstruction, it was excluded 
from the comparison.BMC Genetics 2005, 6:30 http://www.biomedcentral.com/1471-2156/6/30
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were in 100% agreement with those deduced from molec-
ular haplotyping.
Estimation of haplotype frequencies
A comparison of the haplotype frequencies determined
molecularly with those estimated computationally
showed very high concordance. Both PL-EM and PHASE
methods provided similarity index (IF) values very close to
the maximal value of 1 in all investigated data sets (Table
5). Such high values may be explained by the fact that the
IF index gives more weight to common haplotypes whose
frequencies are the most accurately estimated by compu-
tational algorithms. To investigate the effect of haplotype
frequency on estimation accuracy, we plotted the change
coefficient (C) against the larger of the two haplotype
frequencies (Max [ , p0i]), for all possible haplotypes
with nonzero frequency estimates determined by either
analysis in any of the five population samples. As shown
in Figure 3, substantial percentage changes >30% occur
only at the lowest haplotype frequencies (<0.007). Even
the moderate changes (range 10%–30%) occur only when
the frequency estimates are <0.03, and any change in per-
centage value >5% concerns only haplotype frequencies
<0.035. Two-thirds (67%) of the haplotype frequency
estimates showed either no change or a small change (<
3%). In Table 6, we compared the relative estimation
accuracy of PL-EM and PHASE programs by computing
the average change coefficient for three classes of haplo-
type frequencies. The two methods perform similarly for
haplotypes with frequencies >0.05, whereas PHASE pro-
vides more accurate estimates when rarer haplotypes are
concerned.
Partially resolved data sets
We also performed similar analyses on six other previ-
ously published data sets, in which linkage phase patterns
were only partially resolved by molecular haplotyping.
These data concerned 844 German [32], 248 Polish [33],
303 Turkish [34], 50 non-caste Dogons from Mali, 52
Gabonese and 60 Caucasians [5]. Haplotype phase infor-
mation was available for 41%–74% individuals in these
six population samples (including phase-resolved geno-
types as well as non ambiguous homozygous or simply
heterozygous genotypes). The PHASE algorithm was
applied on the unphased genotype multilocus data of
each of these samples, and a 100% concordance was
observed between individual haplotype phase reconstruc-
tion through the computational method and the empiri-
cally determined linkage patterns, for all investigated data
sets (data not shown). This means that, despite the efforts
invested, in terms of work, time and money, to resolve
mutation linkage phase in a part of each sample, no more
information was added by molecular haplotyping than
what could be extracted from computational algorithms
applied to these data.
Discussion
This empirical study demonstrates how closely the fre-
quencies computationally estimated from phase-
unknown data approximate those from gene-counting
estimates based on phase-known data. In the particular
case of the NAT2 gene, where there is near complete LD
between SNPs within the coding region, all in silico
approaches provided highly effective and accurate esti-
mates for haplotype frequencies and individual haplotype
phases. Estimated frequencies of common haplotypes
were nearly identical to those empirically determined,
whereas rare haplotypes were occasionally miscalled
when their presence/absence had to be inferred. As
already pointed out by Stephens et al. [44] and Lin et al.
[39] and confirmed in this study, lower-frequency variants
are less easily estimated statistically; indeed, there is less
contextual information about phase for singletons versus
The change coefficient (C) as a function of haplotype  frequency Figure 3
The change coefficient (C) as a function of haplotype fre-
quency. The change coefficient reflects the discrepancy 
between haplotype frequencies deduced from phase-known 
data and those estimated computationally (here with the 
PHASE program). All haplotypes occurring in any of the five 
population samples are considered.
Table 6: Average change coefficients of PL-EM and PHASE 
programs computed for three classes of haplotype frequency.
Haplotype frequency
< 1% 1–5% > 5%
PL-EM 30.6% 8.3% 1.2%
PHASE 17.4% 6.8% 1.2%
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nonsingletons. Thus, for those research questions for
which the NAT2 common haplotypes are most important,
frequency estimates based on the unphased SNP-typing
results from unrelated individuals will be sufficient. How-
ever, accurate identification of rare haplotypes may be
critical for many researchers, such as population
geneticists interested in detecting features of recent demo-
graphic history that are population-specific or signatures
of selective effects in NAT2 sequences; as well as for epide-
miologists and clinicians concerned with the possibility
that rare haplotypes may be important for disease risk or
for predicting drug response. In such cases, molecular
haplotyping will be necessary to determine linkage phase
unambiguously [57].
For a locus such as NAT2 where a strong haplotypic struc-
ture is observed, all algorithms provided highly effective
and accurate results for haplotype reconstruction. Thus,
such "ideal" data for statistical inference did not permit to
properly discriminate between the different methods
investigated. Nevertheless, despite roughly similar per-
formances, slightly better results were observed with the
PHASE program. In particular, PHASE outperformed the
other programs when frequencies of rare haplotypes have
to be inferred. This is consistent with the results of some
previous studies which evaluated and compared the per-
formance of several algorithms on both empirical and
simulated data [44,54,61]. PHASE provided the most
accurate reconstructions, probably because the true hap-
lotypes conformed more closely to the assumptions of the
approximate coalescent prior than to those of the Dirich-
let prior.
Many factors may influence the estimation accuracy of
computational approaches. They can be assessed empiri-
cally within a dataset, to be further used as "diagnostics"
for predicting potential inaccuracies in estimation caused
by features in the relevant data set [38].
Sample size did not appear to have a large effect on the
haplotype frequency estimates comparing phase-known
and phase-unknown results for the five data sets included
in this study. Perhaps the low error rate observed in Kore-
ans is partly due to the huge size of this sample (1000
individuals): an improvement in accuracy of the estima-
tion procedure with increased sample size is indeed
expected since information redundancy in the form of
multiple copies of the same haplotype in the data set is
required for the statistical algorithms to work properly
[38,48]. On the other hand, computational methods may
also perform best in small samples, in which there is little
chance to observe rare haplotypes that are the most diffi-
cult to infer statistically. Nevertheless, since the number of
new haplotypes is not expected to increase linearly with
sample size, the analysis of sufficiently large samples
should guarantee a good reliability in the resulting
estimates.
Although most of the tested algorithms assume HW equi-
librium, significant departures from HW proportions did
not seem to have any impact on the accuracy of their pre-
dictions. HW equilibrium holds well for the Nicaraguan,
UK Caucasian, and Black South African samples
(nonsignificant results), whereas the genotype
distribution in the Spanish and Korean samples show sig-
nificant departures from HW proportions (Table 2). The
data sets investigated are not the most suitable to evaluate
the effect of a deviation from HW equilibrium: significant
results for tests of HW ratios are quite close to the thresh-
old value (5%), and in the case of the Korean sample, an
excess homozygosity is observed, which should not com-
promise the algorithm performance. Indeed, in such a
case, there is a balance between loss of accuracy caused by
violation of HW equilibrium and gain of accuracy caused
by the decrease in missing phase information through an
excess of homozygotes [38,62].
Among the five data sets investigated in this study, Black
South Africans displayed the highest error rate in haplo-
type computational inference. One possible explanation
may be the presence in this sample of a large number of
different multiple heterozygotes with ambiguous
multilocus genotypes, occurring at roughly similar fre-
quencies (this is reflected in the high NAT2 gene diversity
displayed by this population sample (Table 2)). Indeed,
both the number of different ambiguous multiple hetero-
zygous genotypes and their relative frequencies have been
shown to be of high importance in the assessment of hap-
lotype estimation accuracy [57]: both would be good indi-
cators of the difficulty level of a given data set for
haplotyping algorithms. The existence of many different
multilocus genotypes uniformly distributed implies that
many different haplotypes occur at low frequency, and
that, consequently, greatest error and uncertainty occur in
the estimation of haplotype frequencies (since no single
haplotype is overwelmingly frequent). In contrast, the
presence of a small number of multiple heterozygous
genotypes at proportionately high frequencies implies
that some individual haplotypes exist at high frequencies,
and the estimation of those haplotype frequencies will be
easier and accomplished with greater accuracy [38,57]. In
such cases, molecular haplotyping may add little informa-
tion for the resolution of haplotype phases.
The amount of LD between SNP markers may be another
determining factor for the prediction of estimation relia-
bility since when multiple polymorphic sites display little
disequilibrium, as was observed in the African sample
compared to the others, a large proportion of the chromo-
somes may occur as uncommon or rare haplotypes,BMC Genetics 2005, 6:30 http://www.biomedcentral.com/1471-2156/6/30
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implying a greater difficulty level in the statistical infer-
ence of haplotypes.
Therefore, we advocate to examine beforehand the
unphased NAT2 genotype data for both the frequency dis-
tribution of multiply heterozygous genotypes and the
level of LD between polymorphic markers; this will allow
to assess the difficulty level displayed by the data set for
statistical inference, and hence, to predict the ability and
accuracy with which computational algorithms would
infer haplotype phases from such data.
Of course, statistical methods can be used in conjunction
with experimental methods to provide more accurate esti-
mates of individual haplotypes. It has been claimed that
the ability of certain computational methods to accurately
assess the uncertainty associated with each phase call gives
them the substantial practical advantage of allowing
experimental effort to be directed at sites and/or individu-
als whose phases are most difficult to reconstruct statisti-
cally or that are critical to the conclusions of the study
[20,44,61]. However, in our study, we observed that most
erroneous phase calls inferred at the individual level were
strongly supported, with a probability close to the maxi-
mal value of 1. Thus, these errors could not have been
avoided since they would not have been selected for the
molecular targeting. This stresses why, in the case of the
discovery of a novel NAT2 allele through computational
haplotyping methods, the unusual linkage pattern should
always be confirmed by cloning and sequencing the allele
under question, as advocated by Cascorbi and Roots [25]
for novel allelic combinations detected by molecular
techniques.
Throughout this study, we assumed that the NAT2 linkage
patterns molecularly determined were the "true" ones,
and hence, that there was no error in the haplotype assig-
ments based on experimental methods. However, molec-
ular techniques may have experimental error rates as high
as the rate of statistical error associated with the computa-
tional haplotype determination algorithms [19]. Indeed,
molecular haplotyping bears the risk of false positive or
false negative allele-specific amplification (because of the
nucleotide-dependent specificity of that technique) as
well as uncomplete or non-specific digestions with the
enzymes used in restriction analyses [25]. In the present
study, we have estimated the computational error rates to
be of no more than 3–4% for all investigated algorithms.
This is not higher than the corresponding error rate from
molecular haplotyping techniques, on the order of 2–3%
[20]. Therefore, it is difficult to determine whether the dis-
crepancies observed between experimental and computa-
tional estimates are actually due to statistical errors from
algorithms; they may be due to technical errors during
manipulations and the molecular data used as a reference
for comparisons might be wrong.
The disadvantage of in silico approaches is that algorith-
mic techniques are statistical and require the analysis of a
population rather than a single individual. This is not a
limitation in clinical trials and epidemiological surveys,
which are always performed on a cohort basis. In clinical
pharmacy, however, if a specific individual's haplotypes
are of interest to predict his response to drug treatment,
his unphased multilocus genotype must be combined
with a standard reference set of haplotypes to infer the
phasing [20]. This implies a thorough knowledge of the
NAT2  genotypic distribution in the ethnic population
from which this individual was drawn.
Conclusion
This study demonstrates that computational methods can
provide an effective and accurate prediction of haplotype
phases, in the particular case of the NAT2 gene which dis-
plays high values of LD between polymorphic sites. The
objective of this study is not to advocate the systematic use
of computational approaches for NAT2  haplotype
inference at the expense of molecular haplotyping meth-
ods. We are convinced that these last ones remain the
most reliable and effective way to resolve linkage phase
patterns and that they can produce, for a fixed sample size,
much more precise estimates of haplotype frequencies
than other approaches [63]. However, the considerable
effort required to obtain and analyse individual chromo-
somes make alternative designs preferable; and the in sil-
ico approach appears to be the most practical one. Thus,
for researchers not willing to invest time and money in the
preliminary step of NAT2 haplotype reconstruction, the
use of computational algorithms constitutes a safe and
effective way to get reliable haplotypic data on which fur-
ther analyses could be carried on. Once haplotypes are
constructed, various statistical methods can be applied on
NAT2 haplotype data to detect allele-disease associations
or to classify patients according to their acetylation status.
Methods
NAT2 molecular data sets
To evaluate the performance of in silico approaches in
NAT2 haplotype reconstruction, we based our study on
data collected from the literature, for which linkage phase
was resolved directly through molecular haplotyping.
Molecular data from five previously published data sets
were analysed: they concerned 258 Spanish from Central
Spain [45], 137 Nicaraguans with a Central American
Indian-European mixed origin [30], 112 British from the
Cambridge area [24], 101 Black South Africans (mostly
Tswana-speaking people) [24], and 1000 Koreans [31].
All subjects included in these studies were randomly
selected, unrelated healthy volunteers whose ethnic originBMC Genetics 2005, 6:30 http://www.biomedcentral.com/1471-2156/6/30
Page 10 of 13
(page number not for citation purposes)
had been clearly defined. In each population sample,
seven SNPs were typed at NAT2 for all individuals (no
missing data), and mutation linkage phase of all multiply
heterozygous individuals was resolved molecularly
through allele-specific PCR and restriction mapping. A
summary description of the data sets is given in Table 2.
These data provide an opportunity to compare haplotype
frequencies estimated by direct gene counting on experi-
mentally haplotyped data with haplotype frequencies esti-
mated by haplotyping algorithms when phase
information is ignored.
Throughout this report, we will use the term «phase-
known» to refer to the individual's genetic constitution for
the NAT2 haplotyped system, including the linkage phase
of the component SNP alleles. Whereas we will use the
term "phase-unknown" to refer to an individual's multilo-
cus genotype in the absence of phase information.
Computational haplotyping methods
We evaluated the ability of four population-based haplo-
type inference methods to reconstruct NAT2 haplotypes
from the phase-unknown genotype data.
Hapar
The first method is based on maximum parsimony: it
searches for a set of minimum number of haplotypes that
explain the observed genotype samples. Clark's method,
the first developed algorithm for haplotype reconstruc-
tion [43] which can be viewed as a sort of parsimony
approach, requires homozygote or single-site heterozy-
gote in the sample to start its inferential cascade. Wang
and Xu [46] overcame this limitation by designing an
algorithm with a global optimization goal. This method,
recently implemented in the Hapar program [46], was
tested at its default settings on the phase-unknown NAT2
data.
PL-EM
We also applied the EM algorithm [47] to obtain the max-
imum-likelihood estimates of haplotype frequencies in
the samples, given the observed data [48-50]. This algo-
rithm starts with initial arbitrary values of haplotype fre-
quencies and iteratively updates the frequency estimates,
to maximize the log-likelihood function, until conver-
gence is reached. Several EM-based algorithms have been
developed. We used three different implementations,
Arlequin [51], HAPLO [49] and PL-EM [52], that all gave
us identical results on comparable analyses (data not
shown). Thus, we presented only the results obtained
with the PL-EM program: this software implements an
algorithm derived from the standard EM but incorporat-
ing the computational strategy of partition-ligation [53]
to handle a larger number of loci. We performed 50 inde-
pendent runs with different initial conditions to mini-
mize chances of local convergence so as to ensure finding
the global maximum likelihood estimates. For a given
unphased genotype pattern, the probability of each possi-
ble haplotype configuration was calculated by using the
estimated population haplotype frequencies, and all com-
patible haplotype phases with nontrivial probabilities
were generated. The haplotype pair with the greatest prob-
ability was considered to be the haplotype phase for each
individual, and population haplotype frequencies were
estimated as a function of each inferred haplotype pair,
weighted by their estimated probability.
Haplotyper and PHASE
Finally, two Bayesian statistical methods based on Gibbs
sampling procedure were applied to the phase-unknown
NAT2 data. Such methods treat the unknown haplotypes
as random quantities and combine prior information -
beliefs about what sorts of patterns of haplotypes are
expected to be observed in population samples- with the
likelihood -the information in the observed data [54]. The
conceptual difference between the two investigated Baye-
sian algorithms lies in the prior information incorporated
into the statistical model. The algorithm implemented in
the Haplotyper program [53] uses a Dirichlet prior
distribution, which assumes that the genetic sequence of
a mutant offspring does not depend on the progenitor
sequence [54]. Instead, the algorithm implemented in the
PHASE program [44] uses a prior approximating the coa-
lescent, which is one of the evolutionary models most
commonly used in population genetics (see [55] for a
review): it assumes that unresolved haplotypes will tend
to be the same as, or similar to, known haplotypes. We
employed the lastest version of PHASE (PHASE v 2.1 [54])
to evaluate the performance of this method, using the
default parameter values in the Markov chain Monte
Carlo simulations. For each data set investigated, we
applied the algorithm ten times with different seeds for
the random number generator, and checked for
consistency of the results across the independent runs in
order to verify that the algorithm did not converge to a
local, rather than global, mode of the posterior
distribution. We chose the results from the run displaying
the best average goodness-of-fit of the estimated haplo-
types to the underlying coalescent model. Besides, to eval-
uate the Bayesian algorithm implemented in Haplotyper,
we performed 20 independent runs of the program on
each sample. This software could not be run directly on
the 1000-Korean sample as it can only handle 500 indi-
viduals at most per data set. To circumvent this limitation,
we randomly generated ten pairs of complementary data
sets, each composed of 500 individuals, and we ran Hap-
lotyper on each of them. Results were averaged over the
ten complete data sets. Both programs Haplotyper and
PHASE provide a list of the most likely pairs of haplotypes
for each subject. They also quantify the uncertaintyBMC Genetics 2005, 6:30 http://www.biomedcentral.com/1471-2156/6/30
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associated with each phase call by outputting an estimate
of the probability that each call is correct. This prevents
inappropriate overconfidence in statistically recon-
structed haplotypes.
Measures of estimation accuracy
Computational algorithms of haplotype reconstruction
may be used for many different purposes. We focus here
on three particular tasks: finding the list of all haplotypes
present in a sample, inferring the most likely pair of hap-
lotypes for each sampled individual, and estimating hap-
lotype frequencies in the population. Thus, three different
measures of accuracy were used to evaluate the perform-
ance of the tested algorithms.
-haplotype identification
To assess accuracy in terms of haplotype identification, we
used the IH index introduced by Excoffier and Slatkin [48].
It compares the number of different haplotypes detected
experimentally with the number of different haplotypes
inferred by the computer programs. We considered that a
given haplotype is identified as being present in the true
sample if its estimated frequency is above the threshold
value of 1/(2n) in a population sample of n individuals.
IH is given by:
where ktrue is the number of haplotypes in the true sample,
kest is the number of estimated haplotypes with frequency
above the threshold, and kmissed is the number of true hap-
lotypes not identified in the sample.
Values of IH can vary between 1 (when the computational
identified haplotypes are exactly the same as those deter-
mined experimentally) to 0 (when none of the true hap-
lotypes are identified computationally).
- reconstruction of the haplotypes of each sampled individual
We specified the haplotype pair for an individual by
choosing the most probable haplotype pair consistent
with the individual's multilocus genotype. We measured
performance by the individual error rate, which is the pro-
portion of individuals whose haplotype pairs were incor-
rectly inferred by the program [53].
- estimation of sample haplotype frequencies
To examine how close the computationally estimated
haplotype frequencies are to the observed frequencies in
the phase-known data, we used the similarity index IF of
Renkonen [56], defined as the proportion of haplotype
frequencies in common between the estimated and
observed frequency distributions [18,48].
where   and  p0i denote, respectively, the estimated and
observed sample frequency of the i-th haplotype. This
measure incorporates all h haplotype frequencies and thus
captures the overall difference between estimated and
observed frequencies for a particular data set. It varies
between zero, when true haplotypes have estimated fre-
quencies tending to zero, and one, when observed and
estimated frequencies are identical.
Since this index gives more weight to the high-frequency
haplotypes, we used a second criterion to assess the
accuracy of computational algorithms in haplotype fre-
quency estimation: the change coefficient C, defined in
Tishkoff et al. [57] as
where Max [ , p0i] indicates the maximum value of   or
p0i.
This coefficient measures the percentage change in haplo-
type frequencies across the two information conditions
(phase-known versus phase-unknown data). C  coeffi-
cients were computed for each possible haplotype in each
population. The value of C ranges from 0 to 1, with 0 indi-
cating that the estimated and observed frequency are iden-
tical. The maximal value of 1 indicates that molecular
haplotyping showed either the presence of a haplotype
that was assigned a zero through computational haplotyp-
ing, or vice versa.
Measure of pairwise LD between SNP markers
We used the phase-known data to quantify the amount of
LD between all pairs of polymorphic sites by computing
the correlation coefficient r2 [58] for each population
sample separately. These statistics are expected to be 1
(perfect LD) when the variation is segregating in a popu-
lation as only two distinct haplotypes. Statistical signifi-
cance of LD between pairs of sites was assessed by Fisher's
exact tests. Computations were performed with the soft-
ware PowerMarker v3.21 [59], and a graphical summary
of disequilibrium matrices was displayed by the GOLD
program [60].
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